About Ultromics
Ultromics is a cardiovascular AI company that has developed FDA-cleared, clinically validated artificial intelligence solutions for identifying heart failure and cardiac amyloidosis from routine echocardiography. The company's flagship products, EchoGo® Heart Failure and EchoGo® Amyloidosis, analyze standard apical four-chamber echo views to detect HFpEF and screen for cardiac amyloidosis—two severely underdiagnosed cardiovascular conditions. Founded by Ross Upton (CEO) and Professor Paul Leeson (Chief Medical Officer), Ultromics has built its technology through collaborations with leading research institutions including Mayo Clinic, University of Oxford, and University of Chicago Medicine. The platform is designed to integrate directly into existing PACS, CVIS, and EMR systems through standard DICOM workflows, requiring no changes to scanning protocols or clinical workflows. Results are typically delivered within 20 minutes of study acquisition. Ultromics has achieved FDA 510(k) clearance and Breakthrough Device Designation for both products, with EchoGo® Heart Failure receiving CPT Category III code 0932T from CMS for reimbursement. The company is live in top U.S. hospitals including University Hospitals, City of Hope, University of Wisconsin, and UT Southwestern. Ultromics maintains healthcare compliance certifications including HIPAA, ISO 27001, ISO 13485, and Cyber Essentials. The company works with industry partners including Johnson & Johnson Innovative Medicine and Pfizer, and collaborates with government organizations including the FDA TAP Program, FNIH, and the American Society of Echocardiography.
Mission & Story
Founding Story
Founded by Ross Upton (Founder and Chief Executive Officer) and Professor Paul Leeson (Founder and Chief Medical Officer) to advance cardiovascular care through AI-powered echocardiography analysis
Clinical Focus
Medical conditions and clinical areas addressed by Ultromics.
Who It Serves
Milestones & Awards
Recent Milestones
FDA 510(k) clearance for both products. FDA Breakthrough Device Designation. CMS CPT Category III code 0932T assignment. Live deployment in top U.S. hospitals. Integration with Fujifilm Synapse. Publications in JACC Advances (2023) and European Heart Journal (2025).
Awards & Recognition
FDA Breakthrough Device Designation for both EchoGo® Heart Failure and EchoGo® Amyloidosis
Key Partnerships
Social & Media
Follow on
Latest Updates
Ultromics Secures Strategic Investment from the American Heart Association’s Go Red for Women Venture Fund
7mo ago
Ultromics Secures Strategic Investment from the American Heart Association’s Go Red for Women Venture Fund
7mo ago
Ultromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis
10mo ago
Ultromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis
10mo ago
Ultromics named a WIRED 2025 Trailblazer
10mo ago
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.